Safety and efficacy of TQB2102, a novel bispecific anti-HER2 antibody–drug conjugate, in patients with advanced solid tumors: Preliminary data from the first-in-human phase 1 trial.

Authors: Rui-Hua Xu, Shusen Wang, Dan-yun Ruan, Shaoyan Lin, Fu-Rong Liu, Hao-Xiang Wu, Jia Jia Huang, Qiufan Zheng, Kuikui Jiang, Xiaobo Du, Xiujuan Qu, Ning Li, Yongmei Yin, Yanqiao Zhang, Zhenyang Liu, Junjie Peng, Huihua Xiong, Aili Suo, Rongbo Lin, Shuang Zhang

Published: 2025-05-28

DOI: 10.1200/jco.2025.43.16_suppl.3003

Source: Full article

---

Abstract

3003